Sakura Bio is an innovative biotech company aiming to transform the future of cell therapy with effective, durable, and accessible T and NK cell treatments.

Our core technology, T-Boost, reprograms T and NK cells during the manufacturing process to enhance potency, persistence, and resistance to the tumor microenvironment—addressing critical limitations of current CAR-T and other cell therapies.

T-Boost is a modular, plug-in solution that integrates easily into existing workflows and supports a wide range of modalities, including CAR-T, TCR-T, CAR-NK, TILs, and next-gen approaches for both solid and hematologic tumors.

Backed by strong preclinical data, T-Boost offers a scalable, platform-level opportunity to improve therapeutic outcomes and address major pain points in a fast-growing market.

Our T-boost-derived lead product, Skill-T (Super-Killer T cells), is an off-the-shelf, non-genetically modified allogeneic T-cell therapy.
Skill-T has demonstrated remarkable effectiveness in AML and solid tumors in various models, including mouse models for both AML and ovarian cancer, while maintaining a high safety profile with minimal risk of graft-versus-host disease (GvHD).


Therapeutics

Sakura Bio

Org chart

Teams

Offices

Sakura Bio

Org chart

Teams

Offices

Related companies